Structure Therapeutics Inc (GPCR) reported Q3 2025 results that met analyst expectations. The company posted earnings per share (EPS) of $0.00, surpassing the consensus estimate of $-0.37 by $0.37. Revenue remained at $0.0 billion, consistent with analyst forecasts.
The company will host an earnings conference call to discuss these results and provide further insights into its business performance.
Headquartered in South San Francisco, California, Structure Therapeutics is a clinical-stage biopharmaceutical firm focused on developing novel oral therapeutics for chronic diseases. The company's pipeline includes several programs, such as Aleniglipron, an oral small molecule agonist for obesity, and LTSE-2578, targeting idiopathic pulmonary fibrosis (IPF).
As of November 8, 2025, Structure Therapeutics holds a market capitalization of $1.9 billion, with a trailing twelve-month EPS of -1.04. Upcoming earnings reports are scheduled for May 5, 2026, and August 3, 2026, with EPS estimates of $-0.43 and $-0.42, respectively.